Luitpold Pharmaceuticals, Inc., has quietly been a pioneer in the development and marketing of a wide variety of drugs and medical devices. Each of our subsidiaries and divisions — American Regent, Inc., Luitpold Animal Health, Osteohealth Company, and Contract Manufacturing — offers innovative solutions to our customers across the United States and Canada. To learn more about the exciting work happening at Luitpold Pharmaceuticals, Inc., click on one of the links at the top of this page.
1910: Dr. Karreth launches Luitpold Werk-Chemisch, naming it in honor of the Prince Regent Luitpold of Bavaria.
1946: Natcon Chemical Co. founded in the U.S. as a manufacturer of various pharmaceutical products - ointments, creams, oral elixirs, cough preparations, capsules, and other patented medications
1967: Natcon Chemical Co. starts its American Quinine division, with a strategy of developing "niche" injectable products for the hospital market
Click on the picture to learn more about Luitpold Pharmaceuticals, Inc.
1981: Luitpold-Werk (Germany) acquires Natcon Chemical Co., and changes its name to Luitpold Pharmaceuticals, Inc.
1984: Adequan® i.m. (Polysulfated Glycosaminoglycan) launched in the United States
1987: American Quinine is reorganized and renamed American Regent Laboratories, Inc., with the sole focus of developing and marketing hospital-based injectable products
1989: Adequan® i.m. (Polysulfated Glycosaminoglycan) is launched, offering the benefit of systemic administration for horses.
The Luitpold Animal Health division manufactures and markets pharmaceutical products for the treatment of equine and canine joint diseases including Adequan® i.a., Adequan® i.m., and Adequan® Canine.
Click on the picture to learn more about the Luitpold Animal Health division.
1991: Sanko Company Ltd., Japan's second-largest pharmaceutical company, acquires Luitpold Pharmaceuticals, Inc.
1994: Osteohealth Company, a division of Luitpold Pharmaceuticals, Inc., is launched to market natural source bone regeneration products for use in oral surgery and periodontal procedures
1996: American Regent Laboratories, Inc., launches its first NDA product, Dexferrum® (Iron Dextran Injectable, USP)
1997: Adequan® Canine (Polysulfated Glycosaminoglycan) is launched in the United States
Osteohealth Company is Luitpold's cutting-edge biotechnology division and currently markets products used in dental bone grafting and guided bone regeneration including GEM21S® Growth-factor Enhances Matrix, Bio-Oss®, Bio-Gide®, and Bio-Oss Collagen®.
Click on the picture to learn more about the Osteohealth Company.
2000: Venofer® (iron sucrose injection, USP), manufactured by American Regent, Inc, receives FDA approval for treatment of iron deficiency anemia in hemodialysis patients receiving erythropoietin therapy, and in 2003 becomes the #1 prescribed IV iron in the U.S.
2002: American Regent Laboratories, Inc., is renamed American Regent, Inc.
American Regent, Inc., a wholly-owned subsidiary of Luitpold Pharmaceuticals, Inc., distributes over 65 high-quality injectable products manufactured in our Shirley, NY facility. These products are used in healthcare facilities throughout the United States and Canada. The company has built its outstanding reputation by consistently delivering high-quality products and personalized service to its customers for many years. Our expanding product line and increased manufacturing capabilities are designed to keep pace with the healthcare community's growing demands - now and in the future.
Click on the picture to learn more about American Regent, Inc.
2003: Luitpold Pharmaceuticals, Inc. acquires most of the assets of Protarga, Inc., a development stage pharmaceutical company pioneering Targaceutical® technology
Targaceutical® technology is a novel technology being developed to create a new class of drug products incorporating natural fatty acids to improve drug kinetics and distribution in the body.
Relative to the parent compound, Targaceutical® compounds may have increased pharmacological activity, reduced toxicity, and improved pharmacokinetic properties.
Click on the picture to learn more about Luitpold's Targaceutical® technology.
2005: Venofer® (iron sucrose injection, USP) receives FDA approval for treatment of iron deficiency anemia in Non-Dialysis Dependent - Chronic Kidney Disease (NDD-CKD) patients receiving or not receiving an erythropoietin
Click on the picture to learn more about Venofer® and American Regent Inc.
2005: Osteohealth Company receives FDA approval for GEM21S Growth-factor Enhanced Matrix, the first totally synthetic regeneration system to utilize an active growth factor to enhance the treatment of periodontal bone defects and associated gingival recession.
Osteohealth Company is Luitpold's cutting-edge biotechnology division and currently markets products used in dental bone grafting and guided bone regeneration including GEM21S® Growth-factor Enhanced Matrix, Bio-Oss®, Bio-Gide®, and Bio-Oss Collagen®.
Click on the picture to learn more about the Osteohealth Company.
